Results 81 to 90 of about 54,207 (313)
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. [PDF]
, 2012 BackgroundSrc inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma.MethodsPatients had ECOG performance status 0-2 and normal organ function ...
Algazi, AP +10 more
core
"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL. [PDF]
, 2018 The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured.
Chiaretti, S, Hoelzer, D, Jabbour, E
core +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report [PDF]
, 2014 Case presentation. We report the case of a 64-year-old Caucasian man diagnosed with chronic-phase chronic myeloid leukemia in April 2005. After 4 years of treatment with imatinib, he became intolerant to the drug and was switched to nilotinib.
CAOCCI, GIOVANNI +2 more
core +2 more sources
Glycosylation Gene Signatures as Prognostic Biomarkers in Glioblastoma
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Glioblastoma (GBM) is an aggressive brain tumor characterized by significant heterogeneity. This study investigates the role of glycosylation‐related genes in GBM subtyping, prognosis, and response to therapy. Methods We analyzed mRNA expression data and clinical information from The Cancer Genome Atlas (TCGA) and Gene Expression ...
Tong Zhao +4 more
wiley +1 more source
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Journal of Translational Medicine, 2008 Background Metastatic melanoma is a highly chemotherapy resistant tumour. The use of newer targeted therapies alone and in combination with chemotherapy may offer new hope of improving response to treatment. Dasatinib, a multi-target kinase inhibitor, is
Clynes Martin +3 more
doaj +1 more source
Journal of Inflammation, 2020 Background Neutrophils rapidly respond to and clear infection from tissues, but can also induce tissue damage through excessive degranulation, when acute inflammation proceeds unchecked.
James G. Macfarlane +6 more
doaj +1 more source
Pharmacologic control of CAR-T cell function using dasatinib.
Blood Advances, 2019 Dasatinib potently and reversibly suppresses CAR-T cell cytotoxicity, cytokine secretion, and proliferation. Dasatinib could be repurposed as a safety switch to mitigate CAR-mediated toxicity in patients.
Evan W. Weber +5 more
semanticscholar +1 more source
Blood Advances, 2021 Key Points Dasatinib and dexamethasone induction then allogeneic hematopoietic cell transplantation was feasible and effective for untreated Ph+ ALL. Treatment failure was associated with BCR-ABL1 T315I mutation, the p210 BCR-ABL1 isoform, or isolated ...
M. Wieduwilt +15 more
semanticscholar +1 more source
Optimized Treatment Schedules for Chronic Myeloid Leukemia
, 2016 Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David +4 more
core +3 more sources